News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
WuXi Biologics Chengdu Microbial Manufacturing Site Reaches Structural Completion, Targets 2026 GMP Production
WuXi Biologics announces structural completion of its Chengdu microbial manufacturing facility with key equipment arrival, targeting GMP production by end 2026.
Quasar Medical Opens New Thailand Manufacturing Facility to Expand MedTech Production Capacity
Quasar Medical inaugurates new Chonburi manufacturing facility in Thailand, boosting global production capacity for interventional medical devices.
Daewoong Pharmaceutical NABOTA Master Class Highlights PrabotulinumtoxinA Safety for High-Dose Treatments
Daewoong Pharmaceutical hosted 74 healthcare professionals from 13 countries for NABOTA Master Class, emphasizing PrabotulinumtoxinA safety protocols.
Amcor Opens $35M Healthcare Packaging Facility in Malaysia to Strengthen Southeast Asia Medical Supply Chain
Amcor invests $35M in advanced healthcare packaging facility in Malaysia, bringing sterile medical packaging capabilities to Southeast Asia market.
Transcarent Partners with SmithRx to Expand Pharmacy Benefits Platform for Lower Drug Costs
Transcarent integrates SmithRx into its WayFinding platform to provide employers with enhanced pharmacy pricing transparency and reduced prescription drug costs.
HanchorBio Partners with Bloomberg to Enhance Drug Development Intelligence and Biopharma Strategy
HanchorBio selects Bloomberg's strategic intelligence platform to strengthen its immunotherapy drug development and global biopharma operations.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
Australia's TGA Updates Comprehensive Biologicals Regulatory Framework for Advanced Therapies
Australia's TGA provides updated guidance on biologicals regulation including blood products, tissues, and advanced therapies under ARGB framework.
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Samsung Bioepis launches first-in-human trial for ADC candidate SBE303 and expands Sandoz partnership for five biosimilars including vedolizumab.
Fosun Health Wins Three Awards at GlobalHealth Asia-Pacific Forum 2026, Showcases China Solution Strategy
Fosun Health strengthened its regional presence at GlobalHealth Asia-Pacific Forum 2026, winning three major awards while showcasing its China Solution approach.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
Calluna Pharma Completes CAL101 Phase 2 Enrollment for Idiopathic Pulmonary Fibrosis Treatment
Calluna Pharma enrolls 161 patients in Phase 2 AURORA study of CAL101 for IPF treatment, six months ahead of schedule with topline data expected Q1 2027.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China
Hengrui Pharma reports Q1 2026 growth with three innovative drug approvals including breakthrough anti-PD-L1/TGF-βRII bi-functional fusion protein in China.
Sonorous Neurovascular Receives FDA 510(k) Clearance for BosCATH™ Neurovascular Catheter
Sonorous Neurovascular gains FDA 510(k) clearance for BosCATH™ catheter, advancing neurovascular intervention capabilities for complex cerebral procedures.
Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026
Alphamab Oncology presents clinical data for JSKN016, a novel TROP2/HER3 bispecific ADC targeting HER2-negative breast cancer at ASCO 2026 conference.
RFID Technology Market to Reach $15 Billion by 2032, Transforming Pharmaceutical Supply Chain Management
RFID tags market projected to hit $15 billion by 2032, driven by pharmaceutical serialization mandates and IoT integration for enhanced drug tracking.
WuXi Biologics Receives South Korea GMP Certification for Bispecific Antibody Manufacturing
WuXi Biologics secures South Korea MFDS GMP certification for three facilities, enabling commercial manufacturing of bispecific antibody therapeutics.
Australia's TGA Updates Therapeutic Sunscreen Regulatory Framework for Enhanced Consumer Protection
Australia's TGA provides comprehensive guidance on therapeutic sunscreen regulation, covering application processes, market authorization, and compliance requirements.